Robert (Bob) Alexander, M.D. received his undergraduate and medical degrees from the University of Chicago. He completed an internship in Internal Medicine at the New England Deaconess and a residency in Adult Psychiatry at McLean Hospital/Harvard Medical School. Following residency, Bob was a fellow at the National Institute of Mental Health (NIMH) with the late Richard Wyatt and at Columbia University (in Medical Genetics). As part of his NIMH fellowship he spent one year in the laboratory of Dr. David Sachs of the National Cancer Institute learning positional cloning and other molecular biology techniques. The focus of Bob’s fellowships and early research was in schizophrenia (including investigations into proposed etiologic causes such as the viral and autoimmune hypotheses) and genetics of psychiatric disorders (in particular, genetic animal models informative for addiction and psychosis). Bob was on the faculty of Thomas Jefferson University from 1992 to 1995 and then worked at the University of Pennsylvania, where he developed expertise in the treatment of substance abuse. During his career, Dr. Alexander has held a number of academic positions and hospital appointments and is currently a Staff Psychiatrist at McLean Hospital. Bob is currently the Vice President and Head, Clinical Science, Neuroscience Therapeutic Area Unit at Takeda. Prior to Takeda, Bob was Vice President and Head of Clinical for the Neuroscience and Pain Research Unit; Vice President, Clinical, for CNS and Pain Innovative Medicines Unit (iMed) of AstraZeneca; Vice President and Head of Discovery Medicine and Chief Medical Officer of the Neurosciences Centre for Excellence in Drug Discovery at GlaxoSmithKline; and Senior Director in Clinical Neuroscience and Clinical Pharmacology at Merck Research Labs. Bob is an expert in psychopharmacology and have conducted clinical studies in a broad range of neurologic and psychiatric and targets, including Alzheimer's disease (AD), Parkinson’s dise